XML 61 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Cash flows from operating activities:      
Net loss $ (33,135,404) $ (29,288,867)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 809,559 930,907  
Amortization of intangible assets 136,770 266,563  
Amortization of operating lease right-of-use assets 271,628 0  
Change in fair value of derivative liability 13,221,977 0  
Stock-based compensation 4,001,553 3,432,796  
Non-cash interest expense 213,559 656,248  
Amortization of premiums on investments 0 1,908  
Loss on short-term investments 475,490 35,839  
Settlement of receivable with shares of common stock from affiliated entity (PLS) (1,713,770) 0  
(Gain) loss on equity investment in affiliated entities (13,181,619) 750,103  
Tax benefit from other unrealized gains on short-term investments 0 (217,820)  
Unrealized transaction loss on foreign-currency denominated debt (681,151) 0  
Changes in operating assets and liabilities:      
Accounts receivable 58,430 533,097  
Accounts receivable from affiliated entities 697,846 (557,154)  
Prepaid expenses and other current assets (894,606) 19,789  
Prepaid expenses and other current assets from affiliated entities (740,469) (320,741)  
Other assets 191,937 (311,272)  
Accounts payable and accrued expenses (7,217,676) (6,999,110)  
Accrued clinical trial expenses 1,011,439 1,487,479  
Accounts payable and accrued expenses due to affiliated entities (466,273) 337,818  
Deferred revenue (26,297) (121,873)  
Deferred revenue from affiliated entities (31,250) (31,250)  
Operating lease right-of-use assets and liabilities, net (517,949) (136,388)  
Grant funding liability 7,026,212 (2,886,843)  
Grant funding liability from affiliated entities (49,250) (12,500)  
Other liabilities 36,501 (23,076)  
Net cash used in operating activities (25,452,721) (32,454,347)  
Cash flows from investing activities:      
Purchases of investments (56,698,250) (65,198,491)  
Proceeds from sale or maturity of investments 5,030,257 16,520,095  
Purchases of capital assets (140,952) (658,731)  
Net cash used in investing activities (51,808,945) (49,337,127)  
Cash flows from financing activities:      
Proceeds from issuance of convertible senior notes 0 75,658,953  
Proceeds from issuance of common stock, net of issuance costs 208,241,933 907,330  
Proceeds from stock option exercises 5,173,534 12,334  
Taxes paid related to net share settlement of equity awards (2,072,831) (731,731)  
Acquisition of non-controlling interest 2,169,998 3,030,107  
Net cash provided by financing activities 213,512,634 78,876,993  
Increase (Decrease) in cash and cash equivalents 136,250,968 (2,914,481)  
Cash and cash equivalents, beginning of period 22,196,097 23,693,633 $ 23,693,633
Cash and cash equivalents, end of period 158,447,065 20,779,152 $ 22,196,097
Supplemental disclosures:      
Amounts accrued for purchases of property and equipment 0 68,806  
Interest paid 2,590,196 0  
Right-of-use assets obtained in exchange for lease obligations $ 0 $ 14,634,769